Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial.

Autor: Ruskin JN; Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: jruskin@mgh.harvard.edu., Camm AJ; St. George's University, London, United Kingdom., Dufton C; InCarda Therapeutics, Newark, California, USA., Woite-Silva AC; InCarda Therapeutics, Newark, California, USA., Tuininga Y; Deventer Hospital, Deventer, the Netherlands., Badings E; Deventer Hospital, Deventer, the Netherlands., De Jong JSSG; Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands., Oosterhof T; Ziekenhuis Gelderse Vallei, Ede, the Netherlands., Aksoy I; Admiraal de Ruyter Ziekenhuis, Goes, the Netherlands., Kuijper AFM; Spaarne Gasthuis, Haarlem, the Netherlands., Van Gelder IC; University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., van Dijk V; St Antonius Ziekenhuis, Nieuwegein, the Netherlands., Nuyens D; Hartcentrum Ziekenhuis Oost-Limburg, Genk, Belgium., Schellings D; Slingeland Ziekenhuis, Doetinchem, the Netherlands., Lee MY; Long Beach Medical Center, Long Beach, California, USA., Kowey PR; Lankenau Heart Institute, Wynnewood, Pennsylvania, USA., Crijns HJGM; Maastricht University Medical Center (MUMC), Maastricht, the Netherlands., Maupas J; InCarda Therapeutics, Newark, California, USA., Belardinelli L; InCarda Therapeutics, Newark, California, USA.

Publikováno v: JACC. Clinical electrophysiology [JACC Clin Electrophysiol] 2024 Jun; Vol. 10 (6), pp. 1021-1033. Date of Electronic Publication: 2024 Apr 10.